Chromatin remodeler proteins exert an important function in promoting dynamic modifications in the chromatin architecture, performing a central role in regulating gene transcription. Deregulation of these molecular machines may lead to striking perturbations in normal cell function. The CHD7 gene is a member of the chromodomain helicase DNA-binding family and, when mutated, has been shown to be the cause of the CHARGE syndrome, a severe developmental human disorder. Moreover, CHD7 has been described to be essential for neural stem cells and it is also highly expressed or mutated in a number of human cancers. However, its potential role in glioblastoma has not yet been tested. Here, we show that CHD7 is up-regulated in human glioma tissues and we demonstrate that CHD7 knockout (KO) in LN-229 glioblastoma cells suppresses anchorage-independent growth and spheroid invasion in vitro. Additionally, CHD7 KO impairs tumor growth and increases overall survival in an orthotopic mouse xenograft model. Conversely, ectopic overexpression of CHD7 in LN-428 and A172 glioblastoma cell lines increases cell motility and invasiveness in vitro and promotes LN-428 tumor growth in vivo. Finally, RNA-seq analysis revealed that CHD7 modulates a specific transcriptional signature of invasionrelated target genes. Further studies should explore clinical-translational implications for glioblastoma treatment.
Using both proteomic and genomic approaches, CHD7 was also found to be a transcriptional cofactor of the essential neural stem cell (NSC) regulator, Sox2, suggesting a role for CHD7 in neurogenesis 13 . In this context, CHD7 was shown to be critical for activation of the neural differentiation program of NSC and progenitors in the adult mouse brain 14 and its inactivation resulted in loss of stem cell quiescence, leading to significant decline in the number of newborn neurons 15 . Frequent mutations of CHD7 and/or altered gene expression have been reported in different human cancers [16] [17] [18] [19] . CHD7 (formerly known as KIAA1416) has been reported to be up-regulated in colon cancers 20 and CHD7 gene rearrangement was suggested to be a driver mutation in small-cell lung cancer 21 . Additionally, low CHD7 expression was associated with improved outcome in patients with pancreatic ductal adenocarcinoma treated with gemcitabine 22 . However, the potential contribution of CHD7 to glioblastoma tumor biology had not yet been tested. Using a candidate gene approach, we set out to investigate a possible role for CHD7 in glioblastoma, given its pivotal role for NSC function and the evidence for CHD7 alterations in other tumor types.
Results

CHD7 expression is up-regulated in gliomas.
To investigate a potential role for CHD7 in human glioblastoma, we first examined CHD7 mRNA levels across all glioma grades 23 using the Cancer Genome Atlas Project (TCGA) database. Public microarray database analyses revealed that CHD7 is up-regulated in tumor samples, when compared to normal brain tissue (NBT) (Fig. 1A) , even though no significant alteration in genetic copy number was detected (see supplementary Fig. S1 ). Moreover, we found that CHD7 exhibited different expression patterns when comparing the four transcriptionally defined glioblastoma subtypes 24 with higher levels in the proneural tumor samples (Fig. 1B) .
Consistent with the TCGA interrogation, we confirmed increased CHD7 mRNA levels in glioma tissues by qRT-PCR (Fig. 1C) . Next, we examined the presence of CHD7 expressing cells by immunohistochemistry in *** p < 0.001; 2-way ANOVA followed by Bonferroni posttest. (B) Relative CHD7 mRNA levels in different LTCs and GICs, determined by qRT-PCR. The results represent average ± SEM from two independent experiments. ## p < 0.01, *** p < 0.001; one-way ANOVA followed by Bonferroni correction for multiple tests compared with LN-229 and all the other cell lines, respectively. (C) CHD7 immunoblotting of fractionated nuclear extracts (NE) and cytoplasmic extracts (CE) of LN-229 and LN-319 cell lines. PARP1 and HSP90 were used as nuclear and cytoplasmic markers, respectively, examined consecutively in the same blot as CHD7, after membrane stripping. (D) CHD7 immunoblotting of nuclear extracts of human glioblastoma-derived cell lines. Left panel shows the result from LTCs. In a separate gel, right panel, is the blot from the GICs. Actin was used as loading control for each of the gels. Due to the great difference in the protein sizes, the loading control was examined in a separate gel, loaded under the same conditions. Total protein extract of 293 T cells transfected with the empty vector and CHD7 overexpression plasmids were used as negative and positive controls, respectively.
www.nature.com/scientificreports www.nature.com/scientificreports/ this protein. Initially, we set out to investigate the effect of CHD7 loss-of-function in glioblastoma lines naturally expressing high levels of CHD7. For that purpose, we used the CRISPR/Cas9 genome editing technique to abrogate its expression in LN-229 cells.
Cells were transiently transfected with a combination of two different sgRNA/Cas9 constructs, targeting the initial and final region of the CHD7 gene, aiming to delete most coding exons of CHD7 gene or generate frame shift mutations. After confirming, by PCR, the deletion of genomic DNA in the cell population, we undertook Representative images and statistical plots of transwell Matrigel coated invasion assays. Scale bar: 100 µm. The number of cells which transversed the membrane was assessed after 16 h incubation and six independent fields at 10x magnification objective were counted for each well. Three independent experiments using duplicates were performed for each assay. Results are expressed as average ± SEM. (Fig. 3A,B) . A total of 50 clones were expanded and PCR genotyped, showing that only a few clones presented the fragment deletion, while the amplification targeting the exon 3 sequence was also detected (Supplementary Fig. S3 ). Even though CHD7 deletion did not seem to occur in both alleles, CHD7 immunoblotting showed that several samples did not express the CHD7 protein corresponding to the canonical transcript. Two independent cell clones, in which CHD7 protein was rendered undetectable (KO), along with two control clones, in which CHD7 expression was not altered (WT), were isolated for further analyses (Fig. 3C) . All of these cell clones were successfully expanded in culture without any obvious loss in viability, although clone KO-1 displayed a slightly decreased, albeit significant, difference in growth rate (Fig. 3D) .
Next, we analyzed anchorage-independent growth in a soft-agar colony formation assay. The total number of colonies greater than 50 µm diameter, was consistently decreased in the KO cell clones, when compared to the WT clones (Fig. 3E ). Since anchorage-independent cell growth is associated with neoplastic transformation and metastatic potential, we asked whether the invasion capacity would be affected in the LN-229 KO clones. To that end, we used a 3D-collagen invasion assay to assess invasion in the LN-229 multicellular spheroids, at 24, 48 and 72 h culturing in a serum-containing collagen matrix (Fig. 3F ). The area covered by the invading cells was reduced by about two-fold in the KO clones after 24 h, when compared to the CHD7 expressing clones. The invaded area remained significantly reduced over time, indicating that the invasive potential of the cells was impaired upon CHD7 deletion. Therefore, we demonstrated that CHD7 is not essential for LN-229 cell survival in vitro, however, its deletion affects their anchorage-independent growth and invasiveness.
Ectopic CHD7 overexpression elicits LN-428 cell migration and invasion in vitro. To determine whether the reduced cell invasion capacity observed in LN-229 KO cell clones might originate from a direct effect of CHD7 deletion, we selected the LN-428 cell line, which expresses low level of endogenous CHD7 protein, to generate a cell population that constitutively overexpresses CHD7 (OE). To this end, the full-length CHD7 cDNA was cloned into the mammalian pCXN2-DEST expression vector harboring a very strong promoter for mammalian cells (see supplementary Fig. S4 ). LN-428 cells were transfected with the empty vector (EV) or the CHD7-expressing construct and the G418-resistant polyclonal cell populations were selected and expanded for further analysis. Quantification by qRT-PCR and immunoblotting confirmed CHD7 overexpression in the LN-428 cell line (Fig. 4A) .
We first performed a scratch wound healing assay and we observed that OE cells possessed approximately 30% increased migration potential compared to EV (Fig. 4B ). We also found that CHD7 ectopic expression increased, by almost two-fold, the transwell migration capacity of LN-428 cells (Fig. 4C) . We further investigated the role of CHD7 in modulating tumor cell invasion using the Matrigel invasion assay. CHD7 significantly enhanced, by about six-fold, the invasion capacity of LN-428 cells across the transwell chamber, when compared to cells transfected with the EV (Fig. 4D ).
Immunofluorescence staining of actin filaments was carried out to evaluate whether cytoskeletal alterations could be associated with altered cell motility capacity. We observed over 40% increase in the number of cells displaying stress fibers in OE cells when compared to cells which do not express high levels of the protein ( Similarly, A172 OE cells display significant changes in cell motility and invasiveness, although in a lesser extend (see supplementary Fig. S6 ). Together, these data strongly indicate that CHD7 plays an important role in glioblastoma cell migration and invasion.
CHD7 modulates tumor growth in orthotopic xenograft mouse glioma models. To investigate whether CHD7 is relevant for tumor development and progression, we analyzed whether perturbation of CHD7 protein levels affects the tumorigenic potential of glioblastoma cells in an orthotopic xenograft murine glioma model. Athymic nude mice were used for stereotactical implantation of cells derived from one LN-229 WT clone and two KO clones (n = 8). To measure tumor volume, three pre-randomized mice of each group were sacrificed on the day when the first animal developed neurological symptoms. Analysis of brain sections showed that none of the animals injected with KO cell clones developed big tumors at the time point analyzed, suggesting a delay in tumor growth progression (Fig. 5A,B) . Likewise, mice inoculated with the KO-1 clone experienced prolonged survival rate compared to the WT clone, whereas animals injected with clone KO-2 cells showed a similar effect, although the differences were not statistically significant when compared to the WT clone (Fig. 5C) .
In a similar setting, animals were inoculated with LN-428 OE and EV and the tumor volume was measured (n = 3). The tumor size was significantly increased in OE group, when compared to EV (Fig. 5D) . Immunohistochemistry of brain sections showed that cells displaying high protein levels are located at the border of the tumor (Fig. 5E ) suggesting a correlation between the levels of ectopic CHD7 overexpression and the migration and invasion phenotypes of LN-428 cells in vivo.
Altogether, our results demonstrate that functional deletion of CHD7 in human glioblastoma cells that express high levels of CHD7, may lead to decreased tumor progression, whereas ectopic overexpression of this protein in human glioblastoma cells which express low levels of CHD7, enhances tumor growth and increases cell invasiveness in vivo.
does not display high CHD7 protein level, in comparison with OE cells. Images were captured using confocal microscope. CHD7 (red), Actin filaments (green) and nuclei (blue). Scale bar: 20 µm. (F) Graph shows the percentage of LN-428 cells with low and high CHD7 protein levels which display evident stress fibers. EV and OE cells were plated in three different passages and four independent fields at 20x magnification objective were counted for each well. www.nature.com/scientificreports www.nature.com/scientificreports/ Modulation in CHD7 levels altered the expression of adhesion molecules. Due to the apparent association of CHD7 with glioblastoma pathogenesis, as well as the previously described function of CHD7 in gene transcription 10, 11, 13 , we set out to perform gene expression profiling aimed at gathering molecular insights of the role of CHD7 in human glioblastoma. For that purpose, we carried out whole transcriptome/RNA-seq analysis of those same engineered cell lines in which CHD7 expression has been perturbed.
The comparison between three distinct WT and three isolated CHD7 KO LN-229 cell clones, reveled 307 differentially expressed genes (DEGs) whose expression was significantly altered (FDR < 0.05; abs(LFC) > 1, case over control; see supplementary Table S5) .
Notably, 58 transcripts were commonly regulated in both cell lines, whereas 18 presented alterations in opposite directions in the expression levels between these two groups ( Table 1 ). www.nature.com/scientificreports www.nature.com/scientificreports/ Even though CHD7 seems to regulate distinct genes in LN-229 and LN-428 cells, the altered genes were highly associated with pathways such as "biological adhesion", "cell adhesion" and "locomotion" in gene ontology (GO) analysis (Fig. 6A,B and supplementary Fig. S7) .
Genes encoding proteins involved in cell-cell adhesion, including several integrins (ITGA1, ITGBL1, ITGB2, ITGB3) and protochaderins/cadherins (PCDH7, PCDH10, PCDH15, CDH7, CDH9 and CDH15), as well as other cell binding molecules, such as CADM2, CADM3, NRCAM, NRCAM2, EMILIN2 and CNTN1, were also modulated upon changes in CHD7 expression.
The heat-maps indicate the top 30 DEGs in both groups (Fig. 6C,D) . To independently validate these results, changes in the expression of 40 genes associated with tumorigenesis, cell motility or invasiveness were analyzed by qRT-PCR (Fig. 6E,F) .
Next, we sought to compare the differentially expressed genes found in our model with previously described CHD7 localization determined by chromatin immunoprecipitation in NSCs 13 . These authors revealed approximately 16,000 binding sites near or in the gene sequences. We found that 28% (85 genes) of the DEGs in KO and 30% (259 genes) of the genes modulated in OE coincide with CHD7 binding sites previously mapped in mouse NSCs (see supplementary Table S6 ). These data suggest that CHD7 might have binding sites and/or transcriptional targets that are conserved in between mouse NSCs and human glioblastoma cells.
Discussion
CHD7 is known to be essential for organogenesis 26 and in the non-pathological brain, it was shown to be crucial for NSC function [13] [14] [15] 27 . On the other hand, the involvement of CHD7 in tumorigenesis has just begun to be described, gaining considerable attention in the last few years.
In silico analysis of 32 tumor types revealed that CHD7 is the most commonly gained/amplified and mutated gene among the CHD members. The same study also showed that overexpression of CHD7 was more prevalent in aggressive subtypes of breast cancer, being significantly correlated with high tumor grade and poor prognosis 16 . Consistent with these findings, frequent CHD7 mutations have been reported in stomach and colon cancers 19 and aberrations in CHD7 activity was suggested to contribute to colorectal carcinoma CpG island methylator phenotype 1 18 . Moreover, low CHD7 expression in the G4 meduloblastoma subtype, in combination with BMI1 overexpression, has recently been shown to contribute to tumor formation 17 . Mechanistically, CHD7 inactivation favors chromatin accessibility at BMI1 target genes, which, in turn, leads to ERK over-activity and increased cell proliferation. Thus, these data strongly suggest the association of CHD7 with the pathology of different human cancers.
In the present study, we provide evidence that CHD7 plays an important role in glioblastoma pathogenesis, which is the most common and deadliest of malignant primary brain tumors in adults 28 . Despite the multimodality treatment, which typically includes surgery, ionizing radiation, and cytotoxic chemotherapy, the average overall survival rate remains at only ∼15 months, highlighting the urgent need for more effective targeted therapeutics 29 . www.nature.com/scientificreports www.nature.com/scientificreports/ Our results indicate that CHD7 is highly expressed in glioma patient samples, as previously suggested 30 . Additionally, using the CD133 cell surface marker, we observed that CHD7 is more expressed in the CD133 negative cell population in a subgroup of tumor samples. We also demonstrated that CHD7 knockout not only inhibited anchorage-independent growth in LN-229 cells, but also reduced cell invasion ability. Interestingly, CD133 immunostaining in glioma patient samples showed that CD133 expression was significantly reduced in migrating tumor cells in the tumor periphery compared to tumor cells in the core region 31 . However, the same study discusses that CD133 was found at lower level compared to other stem cell markers, such as Nestin, Musashi-1 and SOX-2.
In vitro, CHD7 expression was found to be highly heterogeneous in the panel of human glioblastoma-derived cell lines analyzed consistent to what we observed in our set of clinical samples as well as in the TCGA public database. Importantly, the cell line presenting the highest CHD7 protein level was the T-269 GIC. Ohta and colleagues have also shown that CHD7 is found to be highly expressed in different established GICs, when compared to normal human astrocytes 30 , however, what specifically determines the great variability in CHD7 expression among these cell lines remains elusive but a warranted field of future investigation.
Studies on CHD7 domain-specific functions and overexpression phenotypes are still scarce in the literature, possibly due to the length of the coding region (2,997 aa) and technical difficulties in generating expression vectors 32 . A recent study showed that introduction of a mRNA encoding the CHD7 isoform 2 (948 aa), in KhES-1 human embryonic stem cells, induced spontaneous cell differentiation in vitro and CHD7-overexpressing cell culture could not be maintained 33 . Here, we amplified the CHD7 coding sequence as three overlapping fragments and the full-length was then assembled and inserted into the expression vector by Gateway ® -assisted sub-cloning.
We demonstrated that ectopic CHD7 expression enhanced migration and invasion capacity of LN-428 cells, potentially by regulating stress fiber assembly and adhesion dynamics. Actin stress fiber formation is one of the critical steps associated with cell invasion 34 , but the precise mechanism by which CHD7 promotes reorganization of the cell cytoskeleton remains to be elucidated. We were unable to explore the role of CHD7 in GICs using the same approach, due to difficulties in selecting and expanding modified cells for experiments.
Interestingly, CHD7 duplications have been suggested to be a driver mutation identified in small-cell lung cancer, one of the most highly metastatic and aggressive types of cancer 21 . Additionally, using iPS-derived neural crest cells from CHARGE patients, CHD7 mutations were also found to promote defective cell migration 35 . This study showed modulation of several genes related to cell adhesion and migration, such as CTGF, COL3A1, SERPINE1 and THBS1, all of which we found to be modulated in glioblastoma cells. CHD7 has also been implicated in regulation of neural crest cell migration during embryogenesis in Xenopus 7 . In this model and also in human neural crest cells, CHD7 was shown to associate with PBAF to modulate SOX9 and TWIST1 gene expression, which are essential for proper cell migration of this cell type. We did not observe significant changes in those genes in our model, indicating that CHD7 may regulate cell motility by different mechanisms, possibly by association with cell-specific interaction partners.
In fact, it has been previously shown that CHD7 binding sites present high variability among different cell types and CHD7 binding itself is context-dependent (e.g., embryonic cell in the differentiated state showed only 30% overlap in the binding sites) 10 . In our study, 18 genes were commonly regulated in opposite directions in LN-229 and LN-428 cell lines. Moreover, the comparison with previously described CHD7 binding sites reveled that genes modulated by CHD7 perturbation in glioblastoma cells, such as NRCAM, CNTN1 and EMILIN2, have significantly higher enrichment of CHD7 occupancy in mouse NSCs 13 , suggesting direct transcription modulation of these targets. Importantly, several of these genes have been implicated in glioblastoma invasiveness 36 . One could argue that each cell type in a given tissue might have unique CHD7 binding sites and protein complexes, which vary over time 32 . Our findings demonstrate the diversity of CHD7-regulated genes and suggest a broader function for CHD7 as a master regulator of cell migration and invasion. It will be of great interest to investigate, for example, the underlying mechanism regulating differential CHD7 expression in glioblastoma cells and whether these pathways are amenable to manipulation by molecular intervention aiming at clinical therapeutic trials.
Conclusions
The invasive behavior of malignant gliomas is one of the most important characteristics which contributes to tumor recurrence after surgery 37 . Our data provides functional and molecular evidences for a novel oncogenic role of CHD7 as a transcriptional regulator of pro-invasive and motility factors in glioblastoma cells (Fig. 6G) . Further studies may warrant important clinical-translational implications for glioblastoma treatment.
Methods
Gene expression and survival analysis using The Cancer Genome Atlas (TCGA) dataset. Overall expression analysis within the TCGA database (http://cancergenome.nih.gov) was undertaken using the single gene expression analysis module of the R2: microarray analysis and visualization platform (http://www.r2.amc.nl). CHD7 expression clusters were generated across 276 samples (MAS5.0 -u133p2 dataset) and analyzed with k-means algorithm and log 2 transformation of gene expression. Analysis of CHD7 expression relative to the glioblastoma subtype 24 was carried out using 435 samples classified into these groups within the subtype track mode and z-score transformation. Kaplan-Meier survival analysis and log-rank tests were carried out as detailed in Supplementary Information.
Patient samples.
Brain tissue samples from temporal lobectomy epileptic patients and from resected astrocytoma specimens were macro-dissected and immediately snap-frozen in liquid nitrogen 38 . The specimens were categorized according to the 2007 WHO classification 23 . This project has the approval of the Ethical Committee of the University of São Paulo School of Medicine (CAPPesq, 691/05), and informed consent was obtained from www.nature.com/scientificreports www.nature.com/scientificreports/ all patients. The CD133 pos and CD133 neg cells were isolated from freshly resected human glioblastoma tumor tissue (ZH-419, ZH-445, ZH-456, ZH-464, ZH-496 and ZH-525) after written informed consent of the patients and approval by the Institutional Review Board of the University Hospital Zurich. Detailed protocol described in Supplementary Information.
In vitro assays. Details on cell lines, reagents, real-time quantitative reverse transcription-PCR (qRT-PCR)
and primers, are provided in Information. Detailed protocol for immunofluorescence, anchorage-independent clonal growth, migration and invasion assays is summarized in Supplementary Information. CRISPR/Cas9 knockout of CHD7. CHD7 knockout clones were generated according to the protocol described by Ran and colleagues 39 . Briefly, small guide RNAs (sgRNAs) were designed, using an CRISPR Design Tool (http://tools.genome-engineering.org) and then cloned (guide sequences in Supplementary Material and Methods Table S2 ) into the pSpCas9(BB)-2A-Puro (PX459), a gift from Feng Zhang (Addgene plasmid #48139, Addgene, Massachusetts, USA). Lipofectamine 2000 (Life Technologies) was used for transient co-transfection of two sgRNAs constructs at a 1:1 ratio. Cells were selected with 3 μg/mL puromycin (Life Technologies) for 48 h and genomic DNA was extracted using QIAamp DNA Kit (Qiagen, Venlo, Netherlands) for detection of the CHD7 deletion by PCR (primer sequences available in Supplementary Information Table S3 ). Transfected cells were then isolated by BD FACSARIA II (BD Bioscience) single cell sorting in 96 well plates. Cell clones were expanded for genomic DNA extraction and genotyping ( Supplementary Fig. S3 ). Selected clones were further expanded for nuclear protein extraction and tested by immunoblotting.
CDH7 overexpression. A 9 Kb cDNA, comprising the ORF full-length of the human CHD7 gene (GenBank Accession #NM_017780.3) was amplified by long RT-PCR from the OVCAR8 human ovarian cancer cell line as three overlapping ~3 kb fragments. Briefly, total RNA was purified from OVCAR8 cells (RNeasy RNA Purification Kit, Qiagen) and 1 μg RNA was used as the template for reverse transcription with SuperScriptIII ® (Life Technologies). PCRs were carried out using Phusion ® High Fidelity DNA Polymerase (New England Biolabs, Ipswich, MA) and the resulting PCR products were cloned using TOPO ® Zero Blunt cloning kit (Thermofisher). Clones displaying the correct sequence, as judged by Sanger sequencing, were assembled by Gibson ® cloning into the full length ORF using the unique AflII and MfeI restriction sites of the CHD7 cDNA. A Kozak consensus sequence was added juxtaposed to the initial ATG codon for optimal expression levels in mammalian cells. The final full-length 9Kb CHD7 cDNA was cloned into the pCXN2 expression vector 40 using the Gateway ® -assisted sub-cloning.
To generate OE cell populations, cells were transfected with the pCXN2_CHD7 construct or with the empty vector using Lipofectamine 2000 (Life Technologies). LN-428 and A172 transfected cells were selected with 750 µg/mL and 200 µg/mL of Geneticin G418 Sulfate (Gibco, Thermo Scientific), respectively.
Histology and immunohistochemistry.
Three glioblastoma patient samples (ZH149, ZH265, ZH276) and one normal brain tissue were used to investigate CHD7 protein levels. Samples were de-paraffinized and rehydrated tumor tissue sections were boiled in EDTA buffer, pre-treated with 1% H 2 O 2 and blocked in blocking solution (Candor Biosciences, Germany). Sections were incubated with primary anti-CHD7 antibodies (ab31824, 1/200) (Abcam, Cambridge, UK) at 4 °C overnight. Simultaneously and under the same conditions, matching rabbit IgG isotype control (ab27478, 1/200) was used in place of the CHD7 primary antibody for accurate interpretation of immunostaining results. After washing, samples were incubated with goat anti-rabbit IgG-AP (sc2007, 1/200) (Santa Cruz, Texas, USA) at room temperature for 30 min (under protection from light). The DAB+ (#K3468, Dako) chromogen substrate was used as the detection system and the sections were counterstained with Mayer's hematoxylin to visualize the nuclei.
Tumor-bearing brains were embedded in cryomoulds in Shandon Cytochrome yellow (Thermo Scientific, Waltham, MA) and frozen in liquid nitrogen. Tumor incidences and sizes were determined using (H&E)-stained 8 μm thick cryosections using a Microm HM560 (Microchom HM560, Thermo Scientific).
Immunoblotting. Total cellular extracts were obtained by lysing cells with RIPA buffer (150 mM, NaCl, 1% NP-40, 0.5% SDS, 50 mM Tris pH 8.2, 1 mM EDTA). Cytoplasm and nuclear protein lysates were prepared with the NE-PER Nuclear and Cytoplasmic Extraction kit (Thermo Scientific). Proteins (30 µg per lane) were resolved on a 3 to 7% Tris-acetate gel (Life Technologies) to detect CHD7 and PARP1. Actin was evaluated in a 10% SDS-PAGE. Gels were transferred to a nitrocellulose membrane (Life Technologies). After blocking with 0.5% non-fat milk in TBS containing 0.5% Tween 20 (TBST), the membrane was incubated in blocking solution with primary antibody overnight at 4 °C. After washing and incubation with the HRP-conjugated secondary antibody (1/5,000, Sigma Aldrich), the protein bands were detected with enhanced chemoluminescence (ECL, Thermo Scientific). Original blots are presented in Supplementary Information, Fig. S8 .
RNA-seq experiment and data analysis. The next-generation sequencing (NGS) libraries were prepared according to Illumina TruSeq Stranded mRNA LT protocol. Quality control of the amplified products before and after fragmentation and labeling was analyzed using the Agilent Bioanalyzer. Samples were sequenced on Illumina NextSeq. 550 (2 × 76 bp paired-end sequencing) operated by the Biomedical Institute Facility Center CEFAP of the University of São Paulo (USP). All calculations were carried out as described in Supplementary Information.
Animal studies. All experiments were carried out according to the Swiss Federal Law on the Protection of Animals, the Swiss Federal Ordinance on the Protection of Animals, and the guidelines of the Swiss confederation (permission #ZH062/15). FoxN1 nu/nu mice (Charles River, Sulzfeld, Germany) aged between 6-12 weeks (2019) 9:3952 | https://doi.org/10.1038/s41598-019-39564-w www.nature.com/scientificreports www.nature.com/scientificreports/ were anaesthetized and placed in a stereotaxic fixation device. A burr hole was drilled in the skull 2 mm lateral and 1 mm posterior to the bregma. The needle of a Hamilton syringe was introduced into a depth of 3 mm 41 . LN-229 (7.5 × 10 4 ) and LN-428 (1 × 10 5 ) cells were resuspended in PBSA and then injected into the right striatum. Animals were clinically assessed three times per week and sacrificed upon developing neurological symptoms, justifying euthanasia (score 2).
Statistics. Analysis of the relative mRNA levels between different glioma grades and glioblastoma samples were carried out by a non-parametric analysis of variance (Kruskal-Wallis test) with Dunn test for post-hoc comparison. In vitro experiments were performed in biological and technical replicates. Results are expressed as the mean and SEM of triplicate determinations. The statistical analyses were performed by unpaired Student's t-test or ANOVA for multiple comparison tests. Animal survival statistics was assessed using Gehan-Breslow-Wilcoxon test. All statistical analyses were carried out using Prism 5 (GraphPad Software, La Jolla, CA).
Ethics approval and consent to participate. Clinical human samples were obtained from patients undergoing surgical resection. All the procedures were performed in accordance with the guidelines and regulations as determined by the Ethical Committee of the University of São Paulo School of Medicine (CAPPesq, 691/05), and informed consents were obtained from all patients. The CD133 pos and CD133 neg cells were isolated from freshly resected human glioblastoma tumor tissue after written informed consent of the patients and in accordance with the guidelines and regulations determined by the Institutional Review Board of the University Hospital Zurich. All animal experiments were performed in accordance with protocols approved by the Swiss Federal Law on the Protection of Animals, the Swiss Federal Ordinance on the Protection of Animals, and the guidelines of the Swiss confederation (permission #ZH062/15).
